{"id":4727,"date":"2025-10-06T14:15:02","date_gmt":"2025-10-06T11:15:02","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4727"},"modified":"2025-10-06T14:51:39","modified_gmt":"2025-10-06T11:51:39","slug":"zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd\/","title":{"rendered":"Le Zydus Lifesciences re\u00e7oit l&#039;approbation du FDA pour le Deflazacort afin de traiter la DMD"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Le lundi 6 octobre, la soci\u00e9t\u00e9 pharmaceutique Zydus Lifesciences a annonc\u00e9 que FDA avait donn\u00e9 son approbation finale pour sa suspension buvable de d\u00e9flazacort \u00e0 la dose de 22,75 mg\/ml. Le produit contient 22,75 mg\/ml de suspension buvable d&#039;Emflaza sous forme g\u00e9n\u00e9rique.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Qu&#039;est-ce que Deflazacort (Emflaza) ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Les patients \u00e2g\u00e9s de cinq ans et plus atteints de dystrophie musculaire de Duchenne (DMD) peuvent \u00eatre trait\u00e9s par la suspension buvable de d\u00e9flazacort. Appartenant \u00e0 la classe des st\u00e9ro\u00efdes, ce m\u00e9dicament contribue \u00e0 r\u00e9duire l&#039;inflammation et \u00e0 calmer un syst\u00e8me immunitaire hyperactif.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selon Zydus, le produit sera fabriqu\u00e9 \u00e0 Doppel, en Italie. Cette homologation porte \u00e0 424 le nombre total d&#039;homologations du groupe.<\/p>","protected":false},"excerpt":{"rendered":"<p>On Monday, October 6, pharmaceutical company Zydus Lifesciences announced that the FDA has given its final approval for its oral suspension of deflazacort at a dose of 22.75 mg\/mL. The product contains 22.75 mg\/mL of Emflaza oral suspension in a generic form. What is Deflazacort (Emflaza)? Patients five years of age and older with Duchenne [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4728,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[211,428,88,429],"class_list":["post-4727","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-deflazacort","tag-emflaza","tag-fda","tag-zydus-lifesciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4727"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4727\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4728"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}